Clinical Trial Update: N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer [Phase 1]

View source ↗

Summary

A phase 1 trial evaluating N-803 in combination with pembrolizumab and enfortumab vedotin for urothelial cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer
• Urothelial Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• N-803
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Vadim S Koshkin | Conditions: Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Status: WITHDRAWN